Data from NSCLC patients demonstrated that KRAS mutation is very low in NSCLC but high in pancreatic cancer, and that it has a significantly lower benefit from EGFR tyrosine kinase inhibitor. The gene discussed is KRAS; the disease is pancreatic neoplasm.